The new clinical trial will test two drugs for the prophylactic treatment of COVID-19 contact persons. (Photo: Louis Brisset, University Hospitals Geneva)
The new clinical trial will test two drugs for the prophylactic treatment of COVID-19 contact persons. (Photo: Louis Brisset, University Hospitals Geneva) - With the easing of measures, there is a pressing need for tools and approaches to contain potential new COVID-19 outbreaks. Academic partners in Geneva and Basel joined forces to launch a clinical trial to test two drugs for the prophylactic treatment of people who were in contact with newly confirmed COVID-19 patients. With the stepwise easing of measures in Switzerland, it is pivotal to monitor for any new COVID-19 outbreaks and to contain them in a timely and effective manner. Today, a clinical trial was launched simultaneously in Geneva and Basel to assess the efficacy of two drugs in the treatment of people who were in close contact with newly confirmed COVID-19 cases. Treating contact-persons of an index patient preventively is called post-exposure ring chemoprophylaxis. "Post-exposure prophylaxis could be a pragmatic approach to contain or slow new outbreaks at an early stage," said Alexandra Calmy, Head of the HIV Unit, Division of Infectious Diseases at the University Hospitals Geneva, who leads the project.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
